Voloridge Investment Management
GPCR icon

Voloridge Investment Management’s Structure Therapeutics GPCR Stock Holding History

Voloridge Investment Management’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.03M Sell
112,300
-142,669
-56% -$6.31M 0.03% 505
2026
Q1 		$12.3M Buy
254,969
+4,969
+2% +$340K 0.05% 451
2025
Q4 		$17.4M Buy
+250,000
New +$10.2M 0.06% 406

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Voloridge Investment Management's GPCR Position: Q2 2026 in Review

Voloridge Investment Management reduced its Structure Therapeutics (GPCR) stake by 56% in Q2 2026, selling an estimated $6.31M and leaving 112,300 shares worth $6.03M. The position accounts for 0.03% of the portfolio, ranked #505.

Voloridge Investment Management first reported a position in GPCR in Q4 2025 and has held it in 3 quarters since. The position peaked at $17.4M in Q4 2025. 191 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • Voloridge Investment Management held 112,300 shares of Structure Therapeutics worth $6.03M as of Q2 2026.
  • Voloridge Investment Management sold 142,669 Structure Therapeutics shares in Q2 2026, an estimated $6.31M.
  • Structure Therapeutics made up 0.03% of Voloridge Investment Management's portfolio in Q2 2026, its #505 holding.
  • Voloridge Investment Management first reported a position in Structure Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Voloridge Investment Management's Structure Therapeutics position peaked at $17.4M in Q4 2025.
  • 191 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on Voloridge Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.